Advanced Portfolio Management LLC Takes Position in Bristol-Myers Squibb (NYSE:BMY)

Advanced Portfolio Management LLC acquired a new position in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 5,636 shares of the biopharmaceutical company's stock, valued at approximately $332,000.

A number of other large investors also recently modified their holdings of the stock. World Investment Advisors LLC raised its position in shares of Bristol-Myers Squibb by 18.7% during the third quarter. World Investment Advisors LLC now owns 44,106 shares of the biopharmaceutical company's stock worth $2,282,000 after purchasing an additional 6,954 shares during the period. Principal Financial Group Inc. boosted its holdings in shares of Bristol-Myers Squibb by 4.4% in the third quarter. Principal Financial Group Inc. now owns 2,458,536 shares of the biopharmaceutical company's stock valued at $127,205,000 after buying an additional 102,790 shares during the period. Versant Capital Management Inc increased its position in shares of Bristol-Myers Squibb by 14.0% during the fourth quarter. Versant Capital Management Inc now owns 78,690 shares of the biopharmaceutical company's stock worth $4,451,000 after acquiring an additional 9,692 shares in the last quarter. GAMMA Investing LLC lifted its position in Bristol-Myers Squibb by 22.0% in the 4th quarter. GAMMA Investing LLC now owns 33,418 shares of the biopharmaceutical company's stock valued at $1,890,000 after acquiring an additional 6,032 shares in the last quarter. Finally, First City Capital Management Inc. lifted its holdings in shares of Bristol-Myers Squibb by 1.0% in the fourth quarter. First City Capital Management Inc. now owns 21,164 shares of the biopharmaceutical company's stock valued at $1,197,000 after purchasing an additional 219 shares in the last quarter. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the company. Citigroup boosted their target price on Bristol-Myers Squibb from $60.00 to $65.00 and gave the company a "neutral" rating in a research note on Tuesday, January 28th. Argus raised shares of Bristol-Myers Squibb to a "hold" rating in a research report on Friday, April 25th. UBS Group dropped their target price on Bristol-Myers Squibb from $60.00 to $54.00 and set a "neutral" rating for the company in a report on Friday, April 11th. Piper Sandler started coverage on Bristol-Myers Squibb in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $65.00 price objective for the company. Finally, The Goldman Sachs Group reiterated a "neutral" rating and set a $55.00 price target (down from $67.00) on shares of Bristol-Myers Squibb in a report on Tuesday, April 8th. Two investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating, five have assigned a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $58.00.

Insider Transactions at Bristol-Myers Squibb

In other news, EVP Samit Hirawat purchased 4,250 shares of the company's stock in a transaction that occurred on Friday, April 25th. The shares were bought at an average price of $47.58 per share, for a total transaction of $202,215.00. Following the purchase, the executive vice president now directly owns 83,513 shares in the company, valued at approximately $3,973,548.54. This trade represents a 5.36 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.09% of the company's stock.

Bristol-Myers Squibb Price Performance

Shares of BMY traded down $2.46 during trading hours on Tuesday, reaching $47.60. 18,505,635 shares of the company's stock traded hands, compared to its average volume of 13,005,675. The firm's 50 day simple moving average is $55.53 and its 200-day simple moving average is $56.39. The company has a current ratio of 1.25, a quick ratio of 1.15 and a debt-to-equity ratio of 2.90. The stock has a market cap of $96.88 billion, a PE ratio of -10.77, a price-to-earnings-growth ratio of 2.07 and a beta of 0.39. Bristol-Myers Squibb has a 12 month low of $39.35 and a 12 month high of $63.33.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last issued its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, topping analysts' consensus estimates of $1.50 by $0.30. The company had revenue of $11.20 billion for the quarter, compared to analysts' expectations of $10.77 billion. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. The firm's revenue was down 5.6% compared to the same quarter last year. During the same quarter last year, the company earned ($4.40) EPS. Equities analysts expect that Bristol-Myers Squibb will post 6.74 EPS for the current year.

Bristol-Myers Squibb Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, May 1st. Shareholders of record on Friday, April 4th were issued a $0.62 dividend. This represents a $2.48 annualized dividend and a yield of 5.21%. The ex-dividend date of this dividend was Friday, April 4th. Bristol-Myers Squibb's dividend payout ratio (DPR) is 92.88%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.